NCT04880382 (OPTIMUNELUNG) is a Phase 2 clinical trial of ICI treatment discontinuation in Non Small Cell Lung Cancer, sponsored by Institut Bergonié.

Who is sponsoring NCT04880382?

NCT04880382 is sponsored by Institut Bergonié.

What drugs are being tested in NCT04880382?

Interventions in NCT04880382: ICI treatment discontinuation, ICI treatment continuation.

What condition does NCT04880382 study?

NCT04880382 studies Non Small Cell Lung Cancer.

Is NCT04880382 still recruiting?

NCT04880382 is currently terminated. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT04880382: OPTIMUNELUNG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients

Terminated Phase 2 Last updated 4 March 2026

What this trial tests

Phase 2 trial testing ICI treatment discontinuation in Non Small Cell Lung Cancer in 8 participants. Terminated before completion.

Timeline

27 August 2021

Primary endpoint
23 February 2026

23 February 2026

Quick facts

Lead sponsor	Institut Bergonié
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	27 August 2021
Primary completion	23 February 2026
Estimated completion	23 February 2026
Sites	5 locations across France

Drugs / interventions tested

ICI treatment discontinuation — full drug profile →
ICI treatment continuation — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Institut Bergonié — full company profile →

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Non-comparative multicentric randomized study to assess long-term benefit of PD-1 inhibition in NSCLC patients who experienced a response between 6 and 12 months after initiation of ICI (immune checkpoint inhibitor PD1/PDL-1 blockade therapy)

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies.
Arandhara A, Bhuyan P, Das BK. · · 2025 · cited 7× · PMID 39934547 · DOI 10.1007/s12672-025-01902-y
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?
Kumar V, Wei XX. · · 2023 · cited 3× · PMID 38993185 · DOI 10.3233/blc-230039
Dose optimization of immune checkpoint inhibitors for gastrointestinal malignancies.
Alsina M, Beunza-Sola M, Fernández-Montes A, Padrón-Rodriguez B, et al · · 2026 · PMID 42180266 · DOI 10.1016/j.esmogo.2026.100338

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Institut Bergonié trials

Trials by the same sponsor.

NCT06084689 — Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures · Phase 2 · withdrawn
NCT06700057 — Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer. · recruiting
NCT05690828 — Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer. · NA · active not recruiting
NCT05415527 — Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Mana · NA · active not recruiting
NCT04912687 — Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04880382 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Bergonié
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04880382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing